Transfection of caspase-3 in the caspase-3-deficient Hodgkin's disease cell line, KMH2, results in enhanced sensitivity to CD95-, TRAIL-, and ARA-C-induced apoptosis

Experimental Hematology

Volumn 29, Issue 5, 2001, Pages 572-581

  Wrone Smith, Tamara ^a   Izban, Keith F ^a   Ergin, Melek ^a   Cosar, Ediz F ^a   Hsi, Eric D ^b   Alkan, Serhan ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 8; CYTARABINE; FAS ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CELL LINE; CONTROLLED STUDY; ENZYME DEFICIENCY; GENETIC TRANSFECTION; HODGKIN DISEASE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD95; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; CASPASE 3; CASPASE 8; CASPASE 9; CASPASES; CYTARABINE; HODGKIN DISEASE; HUMANS; JURKAT CELLS; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; VINCRISTINE;

ARA; PHRAGMITES;

EID: 0035006895     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(01)00627-0     Document Type: Article

References (58)

1. Cossman J., Messineo C., Bagg A. Reed-Sternberg cell. Survival in a hostile sea Lab Invest. 78:1998;229.
2. Kadin M.E. Pathology of Hodgkin's disease. Curr Opin Oncol. 6:1994;456.
3. Gruss H.J., Pinto A., Duyster J., Poppema S., Herrman F. Hodgkin's Disease. A tumor with disturbed immunological pathways Immunol Today. 18:1997;156.
4. Hasenclaver D., Diehl V. A prognostic score for advanced Hodgkin's disease. N Engl J Med. 339:1998;1506.
5. Nagata S., Golstein P. The Fas death factor. Science. 267:1995;1449.
6. Varadhachary A.S., Salgame P. CD95-mediated T cell apoptosis and its relevance to immune deviation. Oncogene. 17:1998;3271.
7. Miller D.K. The role of the caspase family of cysteine proteases in apoptosis. Semin Immunol. 9:1997;35.
8. Thornberry N.A., Lazebnik Y. Caspases. Enemies within Science. 281:1998;1312.
9. Longthorne V.L., Williams G.T. Caspase activity is required for commitment to Fas-mediated apoptosis. EMBO J. 16:1997;3805.
10. Hirata H., Takahashi A., Kobayashi S.et al. Caspases are activated in a branched protease cascade and control distinct downstream processes in Fas-induced apoptosis. J Exp Med. 187:1998;587.
11. Los M., Van de Craen M., Penning L.C.et al. Requirement of an ICE/CED-3 protease for Fas/APO-1-mediated apoptosis. Nature. 375:1995;81.
12. Schlegel J., Peters I., Orrenius S.et al. CPP32/Apopain is a key interleukin 1β converting enzyme-like protease involved in Fas-mediated apoptosis. J Biol Chem. 271:1996;1841.
13. Darmon A.J., Bleackley R.C. An interleukin-1β converting enzyme-like protease is a key component of Fas-mediated apoptosis. J Biol Chem. 271:1996;21699.
14. Reed J.C., Miyashita T., Takayama S.et al. bcl-2 family proteins. Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy J Cell Biochem. 60:1996;23.
15. Gronbaek K., Straten P.T., Ralfkiaer E.et al. Somatic Fas mutations in non-Hodgkin's lymphoma. Association with extranodal disease and autoimmunity Blood. 92:1998;3018.
16. Estrov Z., Thall P.F., Talpaz M.et al. Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood. 92:1998;3090.
17. Xerri L., Devilard E., Hassoun J., Haddad P., Birg F. Malignant and reactive cells from human lymphomas frequently express Fas ligand but display a different sensitivity to Fas-mediated apoptosis. Leukemia. 11:1997;1868.
18. Plumas J., Jacob M.C., Chaperot L., Molens J.P., Sotto J.J., Bensa J.C. Tumor B cells from non-Hodgkin's lymphoma are resistant to CD95 (Fas/Apo-1)-mediated apoptosis. Blood. 91:1998;2875.
19. Nguyen P.L., Harris N.L., Ritz J., Robertson M.J. Expression of CD95 antigen and bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease. Am J Pathol. 148:1996;847.
20. Dirks W., Schone S., Uphoff C., Quentmeier H., Pradella S., Drexler H.G. Expression and function of CD95 (FAS/APO-1) in leukaemia-lymphoma tumour lines. Br J Haematol. 96:1997;584.
21. Kubonishi I., Daibata M., Sakuma I.et al. Expression of Fas and apoptosis of a Hodgkin's disease cell line (HD-70). Int J Hematol. 65:1997;305.
22. Sakuma I., Yoshino T., Omonishi K.et al. CD95 ligand is expressed in Reed-Sternberg cells of Hodgkin's disease. Pathol Int. 49:1999;103.
23. Friesen C., Herr I., Krammer P.H., Debatin K.-M. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med. 2:1996;574.
24. Fulda S., Los M., Friesen C., Debatin K.-M. Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system. Int J Cancer. 76:1998;105.
25. Izban K.F., Wrone-Smith T., Hsi E.D., Schnitzer B., Quevedo M.E., Alkan S. Characterization of the interleukin-1β-converting enzyme/Ced-3-family protease, caspase 3/CPP32 in Hodgkin's disease. Lack of caspase-3 expression in nodular lymphocyte predominance Hodgkin's disease Am J Pathol. 154:1999;1439.
26. Liles W.C., Ledbetter J.A., Waltersdorph A.W., Klebanoff S.J. Crosslinking of CD45 enhances activation of the respiratory burst in response to specific stimuli in human phagocytes. J Immunol. 155:1995;2175.
27. Janicke R.U., Sprengart M.L., Wati M.R., Porter A.G. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem. 273:1998;9357.
28. Fernandes-Alnemri T., Litwack G., Alnemri E.S. CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein ced-3 and mammalian interleukin-1β-converting enzyme. J Biol Chem. 269:1994;30761.
29. Srinivasula S.M., Ahmad M., Macfarlane M.et al. Generation of constitutively active recombinant caspases-3 and -6 by rearrangement of their subunits. J Biol Chem. 273:1998;10107.
30. Nicholson D.W., Ali A., Thornberry N.A.et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 376:1995;37.
31. Jaatela M., Benedict M., Tewari M., Shayman J.A., Dixit V.M. bcl-x and bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells. Oncogene. 10:1995;2295.
32. L can inhibit apoptosis in cells that have undergone Fas-induced protease activation. Proc Natl Acad Sci U S A. 94:1997;3759.
33. Pan G., O'Rourke K., Chinnaiyan A.M.et al. The receptor for the cytotoxic ligand TRAIL. Science. 276:1997;111.
34. Sheridan J.P., Marsters S.A., Pitti R.M.et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 277:1997;818.
35. Mariani S.M., Matiba B., Armandola E.A., Krammer P.H. Interleukin 1β-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells. J Cell Biol. 137:1997;221.
36. Jeremias I., Herr I., Boehler T., Debatin K.-M. TRAIL/Apo-2-ligand-induced apoptosis in human T cells. Eur J Immunol. 28:1998;143.
37. Datta R., Banach D., Kojima H.et al. Activation of the CPP32 protease in apoptosis induced by 1-β-D-Arabinofuranosylcytosine and other DNA-damaging agents. Blood. 6:1996;1936.
38. Los M., Herr I., Friesen C., Fulda S., Schulze-Osthoff K., Debatin K.-M. Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). Blood. 8:1997;3118.
39. Kojima H., Endo K., Moriyama H.et al. Abrogation of mitochondrial cytochrome c release and caspase-3 activation in acquired multidrug resistance. J Biol Chem. 273:1998;16647.
40. Leithauser F., Dhein J., Mechtersheimer G.et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest. 69:1993;415.
41. Owen-Schaub L.B., Meterissian S., Ford R.J. Fas/Apo-1 expression and function on malignant cells of hematologic and non-hematologic origin. J Immunother. 14:1993;234.
42. Ashkenazi A., Dixit V.M. Death receptors. Signaling and modulation Science. 281:1998;1305.
43. Messineo C., Jamerson M.H., Hunter E.et al. Gene expression by single Reed-Sternberg cells. Pathways of apoptosis and activation Blood. 91:1998;2443.
44. Itoh N., Tsujimoto Y., Nagata S. Effect of bcl-2 on Fas-antigen-mediated cell death. J Immunol. 151:1993;621.
45. Weller M., Malipiero U., Aguzzi A., Reed J.C., Fontana A. Protooncogene bcl-2 gene transfer abrogates Fas/Apo-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest. 95:1995;2633.
46. Kornacker M., Verneris M.R., Scheffold C., Negrin R.S. B-cell Hodgkin-Reed-Sternberg cells are resistant to Fas- and chemotherapy-mediated apoptosis but are killed by cytotoxic T-cells. Blood. 92:1998;. 1, Pt. 1, 485aSuppl.
47. Lorenzen J., Thiele J., Fischer R. The mummified Hodgkin cell. Cell death in Hodgkin's disease J Pathol. 182:1997;288.
48. Gupta R.K., Lister T.A., Bodmer J.G. The t(14;18) chromosomal translocation and bcl-2 protein expression in Hodgkin's disease. Leukemia. 8:1994;1337.
49. Schlaifer D., March M., Krajewski S.et al. High expression of the bcl-x gene in Reed-Sternberg cells of Hodgkin's disease. Blood. 85:1995;2671.
50. Brousset P., Benharroch D., Krajewski S.et al. Frequent expression of the cell death-inducing gene Bax in Reed-Sternberg cells of Hodgkin's disease. Blood. 87:1996;2470.
51. Schlaifer D., Krajewski S., Rigal-Huguet F.et al. bcl-x gene expression in Hodgkin's disease. Leuk Lymphoma. 23:1996;143.
52. Brink A.A., Oudejans J.J., van den Brule A.J.et al. Low p53 and high bcl-2 expression in Reed-Sternberg cells predicts poor clinical outcome for Hodgkin's disease. Involvement of apoptosis resistance? Mod Pathol. 11:1998;376.
53. L. J Biol Chem. 271:1996;6306.
54. Micheau O., Solary E., Hammann A., Dimanche-Boitrel M.T. Fas-ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J Biol Chem. 274:1999;7987.
55. Meinhardt G., Roth J., Totok G., Auner H., Emmerich B., Hass R. Signaling defect in the activation of caspase-3 and PKC-δ in human TUR leukemia cells is associated with resistance to apoptosis. Exp Cell Res. 247:1999;534.
56. Srivastava R.K., Srivastava A.R., Korsmeyer S.J., Nesterova M., Cho-Chung Y.S., Longo D.L. Involvement of microtubules in the regulation of bcl-2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol Cell Biol. 18:1998;3509.
57. Chhanabhai M., Krajewski S., Krajewska M., Wang H.G., Reed J.C., Gascoyne R.D. Immunohistochemical analysis of interleukin-1β-converting enzyme/Ced-3 family protease CPP32/Yama/Caspase 3 in Hodgkin's disease. Blood. 90:1997;2451.
58. Xerri L., Devilard E., Ayello C.et al. Cysteine protease CPP32, but not Ich1-L, is expressed in germinal center B cells and their neoplastic counterparts. Hum Pathol. 28:1997;912.